[go: up one dir, main page]

WO2008051760A3 - Combination therapy for the treatment of pain - Google Patents

Combination therapy for the treatment of pain Download PDF

Info

Publication number
WO2008051760A3
WO2008051760A3 PCT/US2007/081598 US2007081598W WO2008051760A3 WO 2008051760 A3 WO2008051760 A3 WO 2008051760A3 US 2007081598 W US2007081598 W US 2007081598W WO 2008051760 A3 WO2008051760 A3 WO 2008051760A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
treatment
combination therapy
present
postoperative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/081598
Other languages
French (fr)
Other versions
WO2008051760A2 (en
Inventor
James Conrad Eisenach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Research and Development Inc
Original Assignee
King Pharmaceuticals Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/872,800 external-priority patent/US20080108603A1/en
Priority claimed from US11/872,878 external-priority patent/US20080113969A1/en
Priority claimed from US11/872,859 external-priority patent/US20080108622A1/en
Application filed by King Pharmaceuticals Research and Development Inc filed Critical King Pharmaceuticals Research and Development Inc
Priority to CA002666925A priority Critical patent/CA2666925A1/en
Publication of WO2008051760A2 publication Critical patent/WO2008051760A2/en
Publication of WO2008051760A3 publication Critical patent/WO2008051760A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides synergistic combinations for the treatment of conditions associated with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain associated with migraine. In particular, the present invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with opioid analgesics or 2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate antagonists for alleviating pain, e.g., postoperative pain.
PCT/US2007/081598 2006-10-19 2007-10-17 Combination therapy for the treatment of pain Ceased WO2008051760A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002666925A CA2666925A1 (en) 2006-10-19 2007-10-17 Combination therapy for the treatment of pain

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US85281506P 2006-10-19 2006-10-19
US60/852,815 2006-10-19
US11/872,800 US20080108603A1 (en) 2006-10-19 2007-10-16 Combination therapy for the treatment of pain
US11/872,878 2007-10-16
US11/872,878 US20080113969A1 (en) 2006-10-19 2007-10-16 Combination therapy for the treatment of pain
US11/872,859 US20080108622A1 (en) 2006-10-19 2007-10-16 Combination therapy for the treatment of pain
US11/872,859 2007-10-16
US11/872,800 2007-10-16

Publications (2)

Publication Number Publication Date
WO2008051760A2 WO2008051760A2 (en) 2008-05-02
WO2008051760A3 true WO2008051760A3 (en) 2008-07-31

Family

ID=39325248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081598 Ceased WO2008051760A2 (en) 2006-10-19 2007-10-17 Combination therapy for the treatment of pain

Country Status (2)

Country Link
CA (1) CA2666925A1 (en)
WO (1) WO2008051760A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100517A1 (en) 2008-03-07 2009-09-16 Bayer CropScience Aktiengesellschaft Use of alternan as texturizing agent in foodstuffs and cosmetics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489356B2 (en) * 2000-09-05 2002-12-03 Edward Leung Method for treating pain in humans
US20040097562A1 (en) * 1996-11-05 2004-05-20 Jes Olesen Method for treating tension-type headache
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097562A1 (en) * 1996-11-05 2004-05-20 Jes Olesen Method for treating tension-type headache
US6489356B2 (en) * 2000-09-05 2002-12-03 Edward Leung Method for treating pain in humans
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain

Also Published As

Publication number Publication date
WO2008051760A2 (en) 2008-05-02
CA2666925A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2007120702A3 (en) Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2008089310A3 (en) Delta 5 desaturase inhibitors for the treatment of obesity
MX2011008450A (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof.
WO2008079460A3 (en) Tyrosine kinase inhibitors for prevention or treatment of infection
WO2007092936A3 (en) Method to treat gastric lesions
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
PH12013500801A1 (en) Formulations for parenteral delivery of compounds and uses thereof
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
MX2009012066A (en) Substituted imidazopyridazines as pi3k lipid kinase inhibitors.
PT2222669E (en) Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
WO2007075555A3 (en) Combination of an h3 antagonist/inverse agonist and an appetite suppressant
MX2009004623A (en) Imidazopyridazines as pi3k lipid kinase inhibitors.
GB2454620A (en) Solid dosage form of olmesartan medoxomil and amlodipine
EP1958621A3 (en) Drug detoxification protocol using microdosing
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
WO2009000843A3 (en) Treatment of heart failure in non-human animal mammals by an aldosterone antagonist
MX2013006004A (en) 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics.
BRPI0911678B8 (en) anhydrous crystalline orvepitant maleate, pharmaceutical composition comprising said maleate and its use for the treatment or prophylaxis of central nervous system diseases
WO2008078715A1 (en) Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854111

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007854111

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009533496

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2666925

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP